Company intelligence / Profile preview

Wasa Medicals

Halmstad, Halland, Sweden

Ownership: Private
Development stage: Other

Overview

ProBion tablets have been shown in clinical trials (BMJ Open Gastroenterology, July 2017) to significantly alter cancer-associated harmful bacteria and increase populations of beneficial, anti-inflammatory bacteria in the gut for colon cancer patients. Controlled-release technology results in high viability of delivered bacteria.

Therapeutic areas: OncologyMetabolic DisordersWomen's HealthGastroenterology
Modalities: Live biotherapeutic product therapy (probiotic tablets)Prebiotic therapy
Industry: Biotech

Drug pipeline

3 assets

ProBion Active

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with universities, hospitals, and research institutions globally

Beyond the preview

Go deeper on Wasa Medicals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wasa Medicals.

Explore the full profile